Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Stock Price, News & Analysis

TCR2 Therapeutics logo

About TCR2 Therapeutics Stock (NASDAQ:TCRR)

Advanced Chart

Key Stats

Today's Range
$1.48
$1.48
50-Day Range
$1.48
$1.98
52-Week Range
$0.82
$3.88
Volume
N/A
Average Volume
494,777 shs
Market Capitalization
$58.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Stock News Headlines

Poseida Therapeutics Inc Ordinary Shares PSTX
DICE Therapeutics Inc.
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
TCR2 Therapeutics Insider Trades Send a Signal
Recap: TCR2 Therapeutics Q1 Earnings
10-Q: TCR2 THERAPEUTICS INC.
See More Headlines

TCRR Stock Analysis - Frequently Asked Questions

TCR2 Therapeutics Inc. (NASDAQ:TCRR) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.06.

TCR2 Therapeutics (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that TCR2 Therapeutics investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Vuzix (VUZI) and SoFi Technologies (SOFI).

Company Calendar

Last Earnings
11/10/2021
Today
7/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TCRR
CIK
1750019
Fax
N/A
Employees
137
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$151.82 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-97.81%
Return on Assets
-69.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.96
Quick Ratio
2.96

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.58 per share
Price / Book
0.57

Miscellaneous

Outstanding Shares
39,260,000
Free Float
29,443,000
Market Cap
$58.10 million
Optionable
Not Optionable
Beta
1.95
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:TCRR) was last updated on 7/27/2025 by MarketBeat.com Staff
From Our Partners